⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16885929 | 0.92 | PDE2A (0.42) | — | |
| SCHEMBL16885923 | 0.87 | ALDH1A1 (0.54) | — | |
| SCHEMBL16885925 | 0.87 | THRB (0.42) | — | |
| SCHEMBL16885926 | 0.85 | ALDH1A1 (0.43) | — | |
| SCHEMBL20093116 | 0.85 | PIK3CD (0.42) | — | |
| SCHEMBL16885922 | 0.84 | CXCR3 (0.43) | — | |
| SCHEMBL8564961 | 0.80 | ALDH1A1 (0.53) | — | |
| SCHEMBL16874550 | 0.80 | KCNH2 (0.51) | — | |
| SCHEMBL8564966 | 0.80 | ALDH1A1 (0.53) | — | |
| SCHEMBL8567056 | 0.78 | ALDH1A1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-29 | — | — | US | disclosed |
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200163949-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-28 | — | — | US | disclosed |
| US-20200163949-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-28 | — | — | US | disclosed |
| US-20190314358-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190314358-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190117638-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190117638-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-25 | — | — | US | disclosed |
| US-20180250283-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-06 | — | — | US | disclosed |
| EP-3092224-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-22 | — | — | EP | disclosed |
| US-20160081995-A1 | Selective NR2B Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160081995-A1 | Selective NR2B Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2016-03-24 | — | — | US | disclosed |
| US-9221796-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221796-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221796-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| WO-2015105772-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015105772-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20150191452-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| US-20150191452-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| US-20150191452-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |